XPO1 Mutations May Identify Binet Α Chronic Lymphocytic Leukemia Patients with Shorter Time to First Treatment

Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Lorenzo De Paoli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mattia Schipani(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sruthi Sagiraju(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Silvia Rasi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Chiara Favini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Clara Deambrogi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ahad Ahmed Kodipad(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alessio Bruscaggin(Institute of Oncology Research), Valeria Spina(Ente Ospedaliero Cantonale), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Blood
November 13, 2019
10.1182/blood-2019-126054
Cited by 3

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
|Blood|2011|268
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|216